Cargando…

Rivaroxaban Treatment for Patients With Unprovoked or Provoked Venous Thromboembolism　― Subanalysis of the J’xactly Study ―

Background: The efficacy and safety of direct oral anticoagulants (DOACs) in patients with unprovoked venous thromboembolism (VTE) remain unclear. Methods and Results: In this subanalysis of the J’xactly study, a multicenter prospective observational study, we evaluated the safety and effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hisatake, Shinji, Ikeda, Takanori, Fukuda, Ikuo, Nakamura, Mashio, Yamada, Norikazu, Takayama, Morimasa, Maeda, Hideaki, Yamashita, Takeshi, Mo, Makoto, Yamazaki, Tsutomu, Okumura, Yasuo, Hirayama, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Circulation Society 2022
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535131/ https://www.ncbi.nlm.nih.gov/pubmed/36304427 http://dx.doi.org/10.1253/circrep.CR-22-0082

Ejemplares similares

Duration of Initial Intensive Rivaroxaban Therapy for Patients With Venous Thromboembolism　― Subanalysis of the J’xactly Study ―
por: Nakamura, Mashio, et al.
Publicado: (2023)

Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J’xactly study
por: Migita, Shohei, et al.
Publicado: (2023)

Prognostication of Patients with Pulmonary Thromboembolism with and without Residual Deep Vein Thrombosis: A Subanalysis of the J’xactly Study
por: Yamada, Norikazu, et al.
Publicado: (2023)

Clinical Outcome After Discontinuation of Anticoagulation Therapy in Japanese Patients With Venous Thromboembolism　― Insights From the J’xactly Study ―
por: Yamashita, Takeshi, et al.
Publicado: (2022)

Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J’xactly) study
por: Okumura, Yasuo, et al.
Publicado: (2018)

Relationship between baseline D-dimer and prognosis in Japanese patients with venous thromboembolism: Insights from the J’xactly study
por: Migita, Shohei, et al.
Publicado: (2023)

Design and Baseline Data for a Prospective Observational Study of Rivaroxaban in Patients with Venous Thromboembolism in Japan (XASSENT)
por: Fukuda, Ikuo, et al.
Publicado: (2021)

Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE
por: Ageno, Walter, et al.
Publicado: (2021)

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
por: Berger, Jeffrey S., et al.
Publicado: (2017)

Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism
por: Wells, Philip S., et al.
Publicado: (2022)

The Use of Rivaroxaban for Unprovoked Pulmonary Embolism in the Setting of Antithrombin Deficiency
por: Gryn, Oscar J, et al.
Publicado: (2020)

Extended anticoagulation for unprovoked venous thromboembolism
por: Castellucci, Lana A., et al.
Publicado: (2018)

Screening for cancer in unprovoked venous thromboembolism
por: Shivji, Salma, et al.
Publicado: (2019)

Is pulmonary embolism occurring after SARS COV-2 vaccination provoked or unprovoked?
por: Catella, Judith, et al.
Publicado: (2022)

Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project
por: Bortoluzzi, Cristiano, et al.
Publicado: (2022)

Unprovoked or provoked venous thromboembolism: not the prevalent criterion to decide on anticoagulation extension in clinical practice of various countries—the prospective, international, observational WHITE study
por: Palareti, Gualtiero, et al.
Publicado: (2021)

Should lifelong anticoagulation for unprovoked venous thromboembolism be revisited?
por: Moodley, Otto, et al.
Publicado: (2015)

Comparison of Clinical and Imaging Characteristics and Outcomes between Provoked and Unprovoked Acute Pulmonary Embolism in Koreans
por: Uhm, Jae-Sun, et al.
Publicado: (2012)

Genetic Risk Profiling Associated with Recurrent Unprovoked Venous Thromboembolism
por: Hodeib, Hossam, et al.
Publicado: (2021)

Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan
por: Nakamura, Mashio, et al.
Publicado: (2017)

Novel Anticoagulant Therapy of Venous Thromboembolism: Current Status and Future Directions
por: Nakamura, Mashio, et al.
Publicado: (2017)

Management of Patients With Unprovoked Venous Thromboembolism: An Evidence-Based and Practical Approach
por: Marcucci, Maura, et al.
Publicado: (2013)

Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism
por: Jara-Palomares, Luis, et al.
Publicado: (2018)

Case Report: Unprovoked venous thromboembolism in a young adult male
por: Dhabhar, Jeyhan, et al.
Publicado: (2019)

Cancer Screening in Patients with Unprovoked Thromboembolism: How to do it and Who Benefits?
por: Ferreira, Filipa, et al.
Publicado: (2020)

Outcomes in infants with unprovoked venous thromboembolism: A retrospective cohort study
por: Whitworth, Hilary, et al.
Publicado: (2023)

Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program
por: Yamada, Norikazu, et al.
Publicado: (2015)

Rivaroxaban Monotherapy in Patients With Atrial Fibrillation and Coronary Stenting at Multiple Vessels or the Left Main Trunk: The AFIRE Trial Subanalysis
por: Ishii, Mitsuru, et al.
Publicado: (2022)

The prevalence and clinical manifestation of hereditary thrombophilia in Korean patients with unprovoked venous thromboembolisms
por: Lee, Su Yeon, et al.
Publicado: (2017)

Long‐Term Effects of Unprovoked Venous Thromboembolism on Mortality and Major Cardiovascular Events
por: Chang, Wei‐Ting, et al.
Publicado: (2017)

Exploring Opportunities for Primary Prevention of Unprovoked Venous Thromboembolism: Ready for Prime Time?
por: Folsom, Aaron R., et al.
Publicado: (2020)

Extensive Unprovoked Thromboembolism in Steroid-Dependent Ulcerative Colitis: A Case Report
por: Arshad, Hassaan, et al.
Publicado: (2023)

Efficacy of bedside optic nerve sheath diameter measurement in differentiating provoked seizure from unprovoked seizure in the emergency department
por: Yılmaz, Fevzi, et al.
Publicado: (2023)

Erratum to: ‘Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program’
por: Yamada, Norikazu, et al.
Publicado: (2016)

Impact of D-Dimer for Prediction of Incident Occult Cancer in Patients with Unprovoked Venous Thromboembolism
por: Han, Donghee, et al.
Publicado: (2016)

Omalizumab as a Provoking Factor for Venous Thromboembolism
por: Oblitas, Crhistian-Mario, et al.
Publicado: (2019)

Rivaroxaban for cancer-associated venous thromboembolism
por: Liang, Bo, et al.
Publicado: (2021)

Answer to an Unprovoked Attack
Publicado: (1884)

Three Cases of Unprovoked Venous Thromboembolism with Prothrombin p.Arg596Gln Variant and a Literature Review of Antithrombin Resistance
por: Tsuji, Akihiro, et al.
Publicado: (2022)

Acute myocardial infarction after initially diagnosed with unprovoked venous thromboembolism: A case report
por: Seo, Jeongduk, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uguu68hqrmhnpahkmdknj3cvcf